Octarepeat changes of prion protein in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue 1, 2009, Pages 53-58

  Wang, Vinchi ^a,b   Chuang, Tzu Chao ^c   Soong, Bing Wen ^d,e   Shan, Din E ^d,e   Kao, Ming Ching ^f,g  

^a CARDINAL TIEN HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TAMKANG UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Copy deletion; Nucleotide substitution; Octarepeat; Parkinson's disease; Polymorphism; Prion protein

Indexed keywords

REPETITIVE DNA;

AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRION;

AGED; DNA MUTATIONAL ANALYSIS; DNA REPEAT EXPANSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PRIONS;

EID: 63049128044     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.03.003     Document Type: Article

References (30)

1. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006;60: 389e98.
2. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004;351:1972e7.
3. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001;21:8447e55.
4. Yoo MS, Chun HS, Son JJ, DeGiorgio LA, Kim DJ, Peng C, et al. Oxidative stress regulated genes in nigral dopaminergic neuronal cells: correlation with the known pathology in Parkinson's disease. Brain Res Mol Brain Res 2003;10:76e84.
5. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005;128:2665e74.
6. Wang V, Chia LG, Ni DR, Cheng LJ, Ho YP, Cheng FC, et al. Effects of the combined treatment of naloxone and indomethacin on catecholamines and behavior after intranigral lipopolysaccharide injection. Neurochem Res 2004;29:341e6.
7. Baker CA, Manuelidis L. Unique inflammatory RNA profiles of microglia in CreutzfeldteJakob disease. Proc Natl Acad Sci USA 2003;100:675e9.
8. Wang V, Chuang TC, Hsu YD, Chou WY, Kao MC. Nitric oxide induces prion protein via MEK and p38 MAPK signaling. Biochem Biophys Res Commun 2005;333:95e100.
9. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN, et al. Diagnosis of new variant CreutzfeldteJakob disease. Ann Neurol 2000;47:575e82.
10. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, Mü ller U, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 2004;63:364e6.
11. Goldfarb LG, Petersen RB, Tabaton M, Brown P, LeBlanc AC, Montagna P, et al. Fatal familial insomnia and familial Creutzfeldte Jakob disease: disease phenotype determined by a DNA polymorphism. Science 1992;258:806e8.
12. Walz R, Castro RM, Velasco TR, Alexandre Jr V, Lopes MH, Leite JP, et al. Surgical outcome in mesial temporal sclerosis correlates with prion protein gene variant. Neurology 2003;61:1204e10.
13. Aronoff-Spencer E, Burns CS, Avdievich NI, Gerfen GJ, Peisach J, Antholine WE, et al. Identification of the Cu2{thorn} binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry 2000;39:13760e71.
14. Sakudo A, Lee DC, Nishimura T, Li S, Tsuji S, Nakamura T, et al. Octapeptide repeat region and N-terminal half of hydrophobic region of prion protein (PrP) mediate PrP-dependent activation of superoxide dismutase. Biochem Biophys Res Commun 2005;326:600e6.
15. Goldfarb LG, Brown P, McCombie WR, Goldgaber D, Swergold GD, Wills PR, et al. Transmissible familial CreutzfeldteJakob disease associated with five, seven, and eight extra octapeptide coding repeats in the PRNP gene. Proc Natl Acad Sci USA 1991;88:10926e30.
16. Wang KC, Wang V, Sun MC, Chiueh TI, Soong BW, Shan DE. Polymorphism distribution of prion protein codon 117, 129 and 171 in Taiwan. Eur J Epidemiol 2007;22:257e61.
17. Scholz SW, Xiromerisiou G, Fung HC, Eerola J, Hellström O, Papadimitriou A, et al. The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations. Neurosci Lett 2006;395:227e9.
18. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, et al. Is M129Vof PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging 2006;27:770. e1e5.
19. Gossrau G, Herting B, Möckel S, Kempe A, Koch R, Reichmann H, et al. Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. J Neural Transm 2006;13:331e7.
20. Wadsworth JD, Asante EA, Desbruslais M, Linehan JM, Joiner S, Gowland I, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004;306:1793e6.
21. Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, et al. Predictors of survival in sporadic CreutzfeldteJakob disease and other human transmissible spongiform encephalopathies. Brain 2004;127:2348e59.
22. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004;364:527e9.
23. Tahiri-Alaoui A, Gill AC, Disterer P, JamesW. Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant: implications for disease susceptibility to CreutzfeldteJakob disease. J Biol Chem 2004;279:31390e7.
24. Kashkevich K, Humeny A, Ziegler U, Groschup MH, Nicken P, Leeb T, et al. Functional relevance of DNA polymorphisms within the promoter region of the prion protein gene and their association to BSE infection. FASEB J 2007;21:1547e55.
25. Thanaraj TA, Clark F. Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Res 2001;29:2581e93.
26. Wu Q, Krainer AR. U1-mediated exon definition interactions between AT-AC and GT-AG introns. Science 1996;274:1005e8.
27. Bocharova OV, Breydo L, Salnikov VV, Baskakov IV. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 2005;44:6776e87.
28. Nadal RC, Abdelraheim SR, Brazier MW, Rigby SE, Brown DR, Viles JH. Prion protein does not redox-silence Cu2{thorn}, but is a sacrificial quencher of hydroxyl radicals. Free Radic Biol Med 2007;42:79e89.
29. Jeong BH, Nam JH, Lee YJ, Lee KH, Jang MK, Carp RI, et al. Polymorphisms of the prion protein gene (PRNP) in a Korean population. J Hum Genet 2004;49:319e24.
30. Brown P, Cervenáková L, Goldfarb LG, McCombie WR, Rubenstein R, Will RG, et al. Iatrogenic CreutzfeldteJakob disease: an example of the interplay between ancient genes andmodern medicine.Neurology 1994;44:291e3.